This, in turn, diminishes their antigen-processing ability, downregulates the costimulatory molecule CD86, and induces excessive expression of the tolerogenic cytokine IL-10, ultimately reducing their ability to activate T cells and promoting tumor immune tolerance—a phenomenon predominantly observed in cDCs but not in pDCs [36]. This evidence concerns the gene CD86 and neoplasm.